Senolytic Drug Combo Dasatinib and Quercetin Accelerates Rotator Cuff Healing in Aged Rats
A senolytic pairing of dasatinib and quercetin cleared senescent cells at the tendon-bone junction, dramatically improving repair strength in aged rats.
Summary
Rotator cuff tears heal poorly in older patients partly because aging accumulates senescent cells that release inflammatory signals and impair tissue regeneration. Researchers tested whether the senolytic drug combination of dasatinib and quercetin — known to selectively eliminate senescent cells — could improve tendon-to-bone healing in aged rats. After surgical repair of chronic rotator cuff tears, treated aged rats showed significantly lower levels of senescence markers and inflammatory cytokines, alongside increased expression of genes driving cartilage and tendon formation. Histological analysis confirmed better tissue organization at the enthesis, and biomechanical testing showed higher failure load, stiffness, and stress compared to untreated aged rats. The findings suggest senolytics may offer a practical strategy to improve surgical outcomes in older patients undergoing rotator cuff repair.
Detailed Summary
Rotator cuff tears are among the most common musculoskeletal injuries in older adults, yet healing after surgical repair remains frustratingly poor with age. A growing body of evidence points to cellular senescence — the accumulation of dysfunctional, inflammation-secreting cells — as a key driver of this age-related healing deficit. This study asked whether clearing those senescent cells with a well-known drug combination could restore the regenerative capacity of aged tissue.
Researchers at Shanghai Sixth People's Hospital used a rat model to first confirm that aged animals (24 months) had significantly higher expression of the senescence marker p21 compared to young adults (6 months), and that rotator cuff surgery amplified this effect further. They then performed chronic rotator cuff repair surgery in young, aged, and aged-plus-DQ groups, evaluating outcomes 12 weeks later.
The dasatinib-and-quercetin (DQ) treated aged rats showed striking reductions in senescence markers p21 and p16, as well as in key SASP factors including IL-6, IL-1β, and MMP-3. Simultaneously, chondrogenic genes (Acan, Col2a1) and tenogenic genes (Col1a1, Tnmd, Scx) were upregulated, indicating a shift toward active tissue repair. Histology confirmed improved cartilage and collagen organization at the enthesis, and biomechanical testing demonstrated meaningfully higher failure load, stiffness, and stress in the DQ group versus untreated aged controls.
These results position senolytics as a potential perioperative adjunct for older patients undergoing rotator cuff surgery — a population with notoriously high re-tear rates. The quercetin component is already widely available as a supplement, and dasatinib is an approved oncology drug, making clinical translation feasible.
Caveats include the animal-only design, reliance on a single rodent model, and the abstract-only basis for this summary. Human pharmacokinetics, dosing, and safety profiles for perioperative DQ use remain to be established.
Key Findings
- DQ treatment reduced senescence markers p21 and p16 at the rotator cuff enthesis in aged rats.
- Inflammatory SASP factors IL-6, IL-1β, and MMP-3 were significantly lower in DQ-treated aged rats.
- Chondrogenic and tenogenic gene expression increased after DQ treatment, signaling active tissue repair.
- Biomechanical testing showed higher failure load, stiffness, and stress in DQ-treated versus untreated aged rats.
- Rotator cuff surgery itself amplified cellular senescence in aged animals, compounding age-related deficits.
Methodology
Controlled laboratory study using young (6-month) and aged (24-month) rats with surgically induced chronic rotator cuff tears followed by repair surgery. Outcomes assessed at 12 weeks post-repair included gene expression, histology, and biomechanical testing of supraspinatus-humerus complexes. Three groups were compared: young vehicle, aged vehicle, and aged treated with dasatinib plus quercetin.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. The study is limited to a rat model, and findings may not translate directly to human biology or clinical settings. Optimal dosing, timing, and safety of perioperative DQ use in humans have not been established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.